Literature DB >> 35559410

Research on antibody changes and nucleic acid clearance in COVID-19 patients treated with convalescent plasma.

Li Duan1, Yudi Xie2, Qiang Wang3, Xianli Sun1, Wenlong Guan1, Jun Xu1, Zhiqiang Lin1, Quan Wang1, Ying Qin1, Chi Zhang1, Yuanda Li1, Xiaojuan Qu1, Ling Li2, Jianping Li4, Guoyue Lin1.   

Abstract

PURPOSE: To investigate changes in the production of IgM and IgG antibodies and the negative transformation of viral nucleic acids in COVID-19 patients after convalescent plasma therapy, and also to discuss the clinical therapeutic effect, so as to provide a basis for the treatment of COVID-19 using specific antibodies.
METHODS: The convalescent plasma of recovered patients from COVID-19 was used to treat other patients, and the levels of antibodies IgM and IgG and the nucleic acid genes ORF1ab and N in the patients were tested regularly for statistical comparison and analysis.
RESULTS: In general, the Ct value and concentration of IgM and IgG antibodies in the plasma infusion group were significantly higher (1-3 times higher) than those in the non-plasma infusion group, respectively, but these differences were not significant (P>0.05). However, the content of antibodies in severe patients in the plasma transfusion group was significantly higher than those in the non-plasma transfusion group at discharge, the results being statistically significant (P<0.05).
CONCLUSIONS: The application of convalescent plasma significantly increases the antibody content in severe and critical inpatients, effectively enhances immune function, accelerates the clearance of virus and the nucleic acid negative conversion rate, and significantly promotes early improvement in COVID-19 patients. AJTR
Copyright © 2022.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; antibody; convalescent plasma; nucleic acid

Year:  2022        PMID: 35559410      PMCID: PMC9091113     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  11 in total

Review 1.  Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses.

Authors:  Zhongyu Zhu; Antony S Dimitrov; Samitabh Chakraborti; Dimana Dimitrova; Xiaodong Xiao; Christopher C Broder; Dimiter S Dimitrov
Journal:  Expert Rev Anti Infect Ther       Date:  2006-02       Impact factor: 5.091

2.  Convalescent Plasma for Ebola Virus Disease.

Authors:  Jose R Arribas; Joanna Luczkowiak; Rafael Delgado
Journal:  N Engl J Med       Date:  2016-06-23       Impact factor: 91.245

3.  Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee.

Authors:  K Mupapa; M Massamba; K Kibadi; K Kuvula; A Bwaka; M Kipasa; R Colebunders; J J Muyembe-Tamfum
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

Review 4.  Origin and evolution of pathogenic coronaviruses.

Authors:  Jie Cui; Fang Li; Zheng-Li Shi
Journal:  Nat Rev Microbiol       Date:  2019-03       Impact factor: 60.633

5.  Calreticulin as a hydrophilic chimeric molecular adjuvant enhances IgG responses to the spike protein of severe acute respiratory syndrome coronavirus.

Authors:  Xiang Qiu; Chao Hong; Yue Li; Wanrong Bao; Xiao-Ming Gao
Journal:  Microbiol Immunol       Date:  2012-08       Impact factor: 1.955

6.  Novel coronavirus: From discovery to clinical diagnostics.

Authors:  Tung Phan
Journal:  Infect Genet Evol       Date:  2020-01-30       Impact factor: 3.342

7.  Use of convalescent plasma therapy in SARS patients in Hong Kong.

Authors:  Y Cheng; R Wong; Y O Y Soo; W S Wong; C K Lee; M H L Ng; P Chan; K C Wong; C B Leung; G Cheng
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

Review 8.  Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities.

Authors:  Yubin Liu; Wei Cao; Ming Sun; Taisheng Li
Journal:  Emerg Microbes Infect       Date:  2020-01-27       Impact factor: 7.163

Review 9.  A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.

Authors:  James D Mellor; Michael P Brown; Helen R Irving; John R Zalcberg; Alexander Dobrovic
Journal:  J Hematol Oncol       Date:  2013-01-04       Impact factor: 17.388

Review 10.  The Role of Complement in Transfusion-Related Acute Lung Injury.

Authors:  Ilse Jongerius; Leendert Porcelijn; Anna E van Beek; John W Semple; C Ellen van der Schoot; Alexander P J Vlaar; Rick Kapur
Journal:  Transfus Med Rev       Date:  2019-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.